• Home

  • Health & Medicine

  • Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant...
42

Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting

Embed Size (px)

Citation preview

Page 1: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 2: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 3: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 4: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 5: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 6: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 7: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 8: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 9: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 10: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 11: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 12: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 13: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 14: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 15: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 16: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 17: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 18: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 19: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 20: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 21: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 22: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 23: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 24: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 25: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 26: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 27: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 28: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 29: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 30: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 31: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 32: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 33: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 34: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 35: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 36: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 37: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 38: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 39: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 40: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 41: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Page 42: Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting

SABCS 2011 Adjuvante Mammakarzinom- Therapie im Wandel Inhalte/PDF/reimer.pdf · Randomisierte Phase II Studie (HER2 positiv neoadjuvant) Kombination Herceptin + Pertuzumab mit Chemotherapie

SABCS 2011 Adjuvante Mammakarzinom- Therapie im Wandel Inhalte/PDF/reimer.pdf · Randomisierte Phase II Studie (HER2 positiv neoadjuvant) Kombination Herceptin + Pertuzumab mit Chemotherapie

Documents
Neoadjuvant chemotherapy for newly diagnosed, advanced ... · Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian ... Neoadjuvant chemotherapy for newly diagnosed, advanced

Neoadjuvant chemotherapy for newly diagnosed, advanced ... · Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian ... Neoadjuvant chemotherapy for newly diagnosed, advanced

Documents
Review Article Neoadjuvant Treatment in Patients with HER2 ...downloads.hindawi.com/journals/isrn/2013/362467.pdf · Review Article Neoadjuvant Treatment in Patients with HER2-Positive

Review Article Neoadjuvant Treatment in Patients with HER2 ...downloads.hindawi.com/journals/isrn/2013/362467.pdf · Review Article Neoadjuvant Treatment in Patients with HER2-Positive

Documents
Pathological Response after Neoadjuvant Chemotherapy in ... · (90%) were Her2 negative. The mastectomy rate was 90.3% in ILC and 75.8% in IDC (p=0.04). The Clinical and Pathological

Pathological Response after Neoadjuvant Chemotherapy in ... · (90%) were Her2 negative. The mastectomy rate was 90.3% in ILC and 75.8% in IDC (p=0.04). The Clinical and Pathological

Documents
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and ... · 5/5/2020  · 41, pathologic complete response (pCR) was associated with prolonged survival among women with HER2-

NSABP B-41, a Randomized Neoadjuvant Trial: Genes and ... · 5/5/2020  · 41, pathologic complete response (pCR) was associated with prolonged survival among women with HER2-

Documents
CURRENT PARADIGMS in HER2-Positive Breast Cancer Neoadjuvant, A djuvant & Metastatic Settings Gunter von Minckwitz, MD, PhD Chairman of German Breast Group

CURRENT PARADIGMS in HER2-Positive Breast Cancer Neoadjuvant, A djuvant & Metastatic Settings Gunter von Minckwitz, MD, PhD Chairman of German Breast Group

Documents
Neoadjuvant Chemotherapy

Neoadjuvant Chemotherapy

Documents
Neoadjuvant (Primary) Systemic Therapy - AGO-Online · Neoadjuvant (Primary) Systemic Therapy ... Neoadjuvant Systemic Chemotherapy ... survival in human epidermal growth factor receptor

Neoadjuvant (Primary) Systemic Therapy - AGO-Online · Neoadjuvant (Primary) Systemic Therapy ... Neoadjuvant Systemic Chemotherapy ... survival in human epidermal growth factor receptor

Documents
Post-Mastectomy Radiation Therapy after Neoadjuvant ... · Neoadjuvant Chemotherapy for Breast Cancer. Outline Case presentation Why neoadjuvant chemo in breast cancer?

Post-Mastectomy Radiation Therapy after Neoadjuvant ... · Neoadjuvant Chemotherapy for Breast Cancer. Outline Case presentation Why neoadjuvant chemo in breast cancer?

Documents
The Clinical trials of Neoadjuvant chemo-hormonal therapy … · 2020. 1. 4. · neoadjuvant hormonal therapy combined with systemic chemotherapy (NCHT), neoadjuvant hormonal therapy

The Clinical trials of Neoadjuvant chemo-hormonal therapy … · 2020. 1. 4. · neoadjuvant hormonal therapy combined with systemic chemotherapy (NCHT), neoadjuvant hormonal therapy

Documents
New Drug Development in HER2+ Breast Cancer › pdf › 3. AFTIMOS.pdf · The Trastuzumab (Herceptin®) Story 1979: HER2 oncogene discovery 1984: HER2 protein discovery 1987: HER2

New Drug Development in HER2+ Breast Cancer › pdf › 3. AFTIMOS.pdf · The Trastuzumab (Herceptin®) Story 1979: HER2 oncogene discovery 1984: HER2 protein discovery 1987: HER2

Documents
A Neoadjuvant/Adjuvant Standards of Care and Experimental ...Executive Director: Smita Asare Program Administration: ... HR+HER2-Estimated pCR rate (%) HR-HER2-all patient data from

A Neoadjuvant/Adjuvant Standards of Care and Experimental ...Executive Director: Smita Asare Program Administration: ... HR+HER2-Estimated pCR rate (%) HR-HER2-all patient data from

Documents
SAUDI BREAST CANCER MANAGEMENT GUIDELINES...4.2 Neoadjuvant Chemotherapy for Her2 amplified tumor. 4.1.1 Three-Four cycles of Anthracycline based regimen followed by 3-4 cycles of

SAUDI BREAST CANCER MANAGEMENT GUIDELINES...4.2 Neoadjuvant Chemotherapy for Her2 amplified tumor. 4.1.1 Three-Four cycles of Anthracycline based regimen followed by 3-4 cycles of

Documents
Neoadjuvant Imatinib, Surgery and then ?

Neoadjuvant Imatinib, Surgery and then ?

Documents
Management of HER2 Over- Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings Christy A Russell, MD Keck School of Medicine University

Management of HER2 Over- Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings Christy A Russell, MD Keck School of Medicine University

Documents
TREATMENT FOR HER2-positive (HER2+) early breast cancer...In a clinical study of 1,486 people with HER2+ early breast cancer who had residual disease after receiving neoadjuvant medicine

TREATMENT FOR HER2-positive (HER2+) early breast cancer...In a clinical study of 1,486 people with HER2+ early breast cancer who had residual disease after receiving neoadjuvant medicine

Documents
Standards for neoadjuvant Treatment

Standards for neoadjuvant Treatment

Documents
What’s New in HER2: Current Issues in HER2 Positive Breast Cancer

What’s New in HER2: Current Issues in HER2 Positive Breast Cancer

Documents
What’s NeW INPathology · in Breast Cancer Surgical Specimens • Neoadjuvant chemotherapy is routinely used for triple negative and HER2 positive tumors (Fig. 4). • Multiple

What’s NeW INPathology · in Breast Cancer Surgical Specimens • Neoadjuvant chemotherapy is routinely used for triple negative and HER2 positive tumors (Fig. 4). • Multiple

Documents
Therapeutic targeting of HER2 CB2R heteromers in HER2 ... · previously reported the presence of these complexes in HER2+ breast cancer tumors (12), but their role in HER2 function

Therapeutic targeting of HER2 CB2R heteromers in HER2 ... · previously reported the presence of these complexes in HER2+ breast cancer tumors (12), but their role in HER2 function

Documents
Activating HER2 Mutations in HER2 Gene ... - Cancer Discovery · 224 | CANCER DISCOVERYFEBRUARY 2013 Activating HER2 Mutations in HER2 Gene Amplifi cation Negative Breast Cancer

Activating HER2 Mutations in HER2 Gene ... - Cancer Discovery · 224 | CANCER DISCOVERYFEBRUARY 2013 Activating HER2 Mutations in HER2 Gene Amplifi cation Negative Breast Cancer

Documents
HER2 Gene Mutations in Non-Small Cell Lung Carcinomas: Concurrence with HER2 Gene ... · 2016-03-16 · HER2 Gene Mutations in Non-Small Cell Lung Carcinomas: Concurrence with HER2

HER2 Gene Mutations in Non-Small Cell Lung Carcinomas: Concurrence with HER2 Gene ... · 2016-03-16 · HER2 Gene Mutations in Non-Small Cell Lung Carcinomas: Concurrence with HER2

Documents
Review Article Neoadjuvant Treatment in Patients …downloads.hindawi.com/archive/2013/362467.pdfNeoadjuvant Treatment in Patients with HER2-Positive Breast Cancer KatarinaSevcikova,

Review Article Neoadjuvant Treatment in Patients …downloads.hindawi.com/archive/2013/362467.pdfNeoadjuvant Treatment in Patients with HER2-Positive Breast Cancer KatarinaSevcikova,

Documents
COMBATing Molekulare Erklärungen für klinische ... · after HER2+ status loss HER2 pos --> HER2 pos HER2neg --> HER2neg .044 significant difference HER2+ Status loss Primary Met

COMBATing Molekulare Erklärungen für klinische ... · after HER2+ status loss HER2 pos --> HER2 pos HER2neg --> HER2neg .044 significant difference HER2+ Status loss Primary Met

Documents
Breast Pathology Post-Neoadjuvant Chemotherapy · Breast Pathology Post-Neoadjuvant Chemotherapy Megan Troxell, ... advanced breast cancer . ... Breast Pathology Post-Neoadjuvant

Breast Pathology Post-Neoadjuvant Chemotherapy · Breast Pathology Post-Neoadjuvant Chemotherapy Megan Troxell, ... advanced breast cancer . ... Breast Pathology Post-Neoadjuvant

Documents
Her2 seleccion

Her2 seleccion

Documents
Tionde nordiska symposiet om HER2-positiv bröstcancer · 2018. 1. 31. · större än 3 cm samt inflammatorisk sjukdom, rekommen-derar Sandra Swain neoadjuvant behandling med docetaxel,

Tionde nordiska symposiet om HER2-positiv bröstcancer · 2018. 1. 31. · större än 3 cm samt inflammatorisk sjukdom, rekommen-derar Sandra Swain neoadjuvant behandling med docetaxel,

Documents
Inhibition of abnormal HER2-driven signaling by two HER2 ...€¦ · • These results suggest a new sub-group of breast cancer patients, HER2- with abnormal HER2 signaling (HER2-/HER2

Inhibition of abnormal HER2-driven signaling by two HER2 ...€¦ · • These results suggest a new sub-group of breast cancer patients, HER2- with abnormal HER2 signaling (HER2-/HER2

Documents
Neoadjuvant treatment strategies for locally advanced rectal cancereprints.whiterose.ac.uk/93146/3/v4 Neoadjuvant Rectal... · 2018-03-23 · Gollins and Sebag-Montefiore Neoadjuvant

Neoadjuvant treatment strategies for locally advanced rectal cancereprints.whiterose.ac.uk/93146/3/v4 Neoadjuvant Rectal... · 2018-03-23 · Gollins and Sebag-Montefiore Neoadjuvant

Documents
Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer

Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer

Documents